Enhancing Capital LLC Invests $476,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

Enhancing Capital LLC bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, Holdings Channel reports. The firm bought 1,434 shares of the company’s stock, valued at approximately $476,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Pallas Capital Advisors LLC boosted its position in Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after buying an additional 2,101 shares during the last quarter. Barclays PLC boosted its position in Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after buying an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC boosted its position in Medpace by 20.5% in the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock valued at $1,738,000 after buying an additional 844 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in Medpace in the 3rd quarter valued at $3,098,000. Finally, Loomis Sayles & Co. L P lifted its stake in shares of Medpace by 7.2% in the 3rd quarter. Loomis Sayles & Co. L P now owns 205,798 shares of the company’s stock valued at $68,696,000 after purchasing an additional 13,880 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Medpace presently has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Trading Down 1.0 %

Shares of Medpace stock opened at $322.93 on Wednesday. The company has a market capitalization of $9.84 billion, a PE ratio of 25.57, a PEG ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The stock’s fifty day simple moving average is $339.49 and its 200 day simple moving average is $340.34.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.